Insulin

Technosphere insulin, a rapid-acting human insulin administrated through an inhaler, was associated with reductions in HbA1c at 30 weeks for adults with type 1 diabetes, according to findings from the INHALE-3 extension trial.

Adults with insulin-treated type 2 diabetes had greater HbA1c reductions and larger improvement in time in range with use of an automated insulin delivery system compared with standard care, according to findings from a new trial.

Diabetes mortality declined in the U.S. by 32.1% from 2000 to 2019, with decreases in mortality observed among all racial and ethnic groups and in most U.S. counties, researchers reported in Diabetes Care.

The FDA has approved the first rapid-acting biosimilar insulin product for glycemic control in people with diabetes.

Surrogate measures of insulin resistance, based on the triglyceride-glucose index, can be used to predict the development of osteoarthritis, according to data published in Scientific Reports.

Hybrid closed-loop systems outperformed other types of subcutaneous insulin treatment for diabetes, but some systems were more efficient than others, according to results published in Diabetes/Metabolism Research and Reviews.

Patients with type 2 diabetes uncontrolled by metformin who received pioglitazone and insulin demonstrated increased risk for ischemic heart disease, according to findings published in the Journal of Diabetes and Its Complications.

From 1990 to 2022, diabetes prevalence rose greatly, but for the most part, treatment did not increase at all or sufficiently, especially in low- and middle-income countries, researchers reported in The Lancet.

A novel duodenal mucosal renewal procedure followed by once-weekly semaglutide could allow adults with type 2 diabetes to maintain glycemic control without insulin therapy, according to a speaker.

The Federal Trade Commission announced it has filed an administrative complaint against three pharmacy benefit managers alleging “anticompetitive and unfair” rebate practices that have artificially inflated the price of insulin drugs.